CG Oncology (CGON)

• Market cap: $3.36B
• 1 day: 3.27%
• 5 days: 3.86%
• 1 month: -2.59%
• 3 months: 9.71%
• 6 months: 58.82%
• Year to date: -0.24%
• 1 year: 34.44%
• 5 years: 12.16%
• 10 years: 12.16%
• Sector: Healthcare
• Industry: Biotechnology

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113